Megan Osele

Megan Osele serves as a Contracting Officer within the National Cancer Institute, part of the National Institutes of Health, where she manages complex procurements supporting cutting-edge cancer research and translational science. Her portfolio centers on acquiring advanced biotechnology research services, diagnostic platforms, and pharmaceutical manufacturing capabilities critical to advancing precision oncology. Osele plays a pivotal role in executing acquisitions aligned with NCI’s mission to accelerate the development of novel therapeutics, genomic analysis tools, and molecular diagnostics, ensuring compliance with federal procurement regulations while fostering innovation in high-impact scientific domains. Her primary contractor relationships are dominated by Roche Diagnostics Corporation, reflecting a strategic reliance on industry leaders with proven capabilities in in vitro diagnostics, oncology assays, and integrated laboratory systems. Osele consistently engages with large, technically sophisticated vendors capable of delivering GMP-compliant manufacturing, CLIA-certified testing platforms, and scalable R&D infrastructure. Her contracting approach emphasizes technical rigor, performance-based outcomes, and long-term partnership stability, favoring vendors with demonstrated expertise in translational research and regulatory readiness. Osele’s procurement portfolio reflects a strong preference for full and open competition, with 100% of her awards issued under no set-aside categories. This underscores a mission-driven focus on securing the highest-capability solutions available in the marketplace, prioritizing technical merit and scientific impact over socioeconomic preferences. While small business participation is not structurally prioritized in her awards, her acquisitions remain compliant with all federal small business goals, and she routinely evaluates small business capabilities as part of technical evaluations. Her primary NAICS focus areas are 541714 (Research and Development in Biotechnology) and 325412 (Pharmaceutical Preparation Manufacturing), reflecting deep expertise in procuring next-generation sequencing services, biomarker validation platforms, and GMP-grade oncology drug formulations. Osele’s technical acumen spans molecular diagnostics, clinical trial support systems, and automated laboratory workflows, positioning her as a key enabler of NCI’s mission to translate scientific discovery into clinical impact.